Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers

Over the past two decades, lactic acid bacteria (LAB) have been intensively studied as potential bacterial carriers for therapeutic materials, such as vaccine antigens, to the mucosal tissues. LAB have several attractive advantages as carriers of mucosal vaccines, and the effectiveness of LAB vaccin...

Full description

Saved in:
Bibliographic Details
Published in:Applied microbiology and biotechnology 2019-08, Vol.103 (15), p.5947-5955
Main Authors: Takahashi, Keita, Orito, Nozomi, Tokunoh, Nagisa, Inoue, Naoki
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Bacteria
Biomedical and Life Sciences
Biotechnology
Cell-mediated immunity
Computer memory
Contamination
Health aspects
Immune response
Immunity
Immunological memory
Immunology
Lactic acid
Lactic acid bacteria
Life Sciences
Medical research
Medicine, Experimental
Memory (Computers)
Memory cells
Microbial Genetics and Genomics
Microbiology
Microbiota
Microbiota (Symbiotic organisms)
Mini-Review
Mucosa
Vaccine development
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past two decades, lactic acid bacteria (LAB) have been intensively studied as potential bacterial carriers for therapeutic materials, such as vaccine antigens, to the mucosal tissues. LAB have several attractive advantages as carriers of mucosal vaccines, and the effectiveness of LAB vaccines has been demonstrated in numerous studies. Research on LAB vaccines to date has focused on whether antigen-specific immunity, particularly antibody responses, can be induced. However, with recent developments in immunology, microbiology, and vaccinology, more detailed analyses of the underlying mechanisms, especially, of the induction of cell-mediated immunity and memory cells, have been required for vaccine development and licensure. In this mini-review, we will discuss the issues, including (i) immune responses other than antibody production, (ii) persistence of LAB vaccine immunity, (iii) comparative evaluation of LAB vaccines with any existing or reference vaccines, (iv) strategies for increasing the effectiveness of LAB vaccines, and (iv) effects of microbiota on the efficacy of LAB vaccines. Although these issues have been rarely studied or discussed to date in relation to LAB vaccine research, further understanding of them is critical for the practical application of LAB vaccine systems.
ISSN:0175-7598
1432-0614
DOI:10.1007/s00253-019-09912-x